首页> 外文期刊>Nature reviews. Urology >Kidney cancer: Low serum sodium linked to poor outcomes for patients with mRCC treated with targeted therapy
【24h】

Kidney cancer: Low serum sodium linked to poor outcomes for patients with mRCC treated with targeted therapy

机译:肾癌:靶向治疗治疗的mRCC患者血清钠水平低与预后不良相关

获取原文
获取原文并翻译 | 示例
           

摘要

Baseline hyponatraemia (serum sodium level of < 135 mmol/l) is associated with poor overall survival, time to treatment failure (TTF), and disease control rate (DCR) in patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy, according to a recent analysis of data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
机译:基线低钠血症(血清钠水平<135 mmol / l)与接受靶向治疗的转移性肾细胞癌(mRCC)患者的不良生存率,治疗失败时间(TTF)和疾病控制率(DCR)有关,根据国际转移性肾细胞癌数据库联盟(IMDC)对数据的最新分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号